Featuring an interview with Dr Eric Sherman, including the following topics:
- Changes in the incidence, mortality, and management of thyroid cancer in the past 20 years (0:00)
- Clinical presentation and histologic characteristics of thyroid cancer; genomic alterations associated with each histology (5:55)
- Initial management of thyroid cancer; current role of surgery and radioactive iodine in treatment algorithms (14:56)
- Current and future role of tumor biomarkers in treatment selection; emerging role of liquid biopsies in anaplastic thyroid cancer (20:23)
- Incidence and optimal treatment of brain metastases in patients with thyroid cancer; biologic rationale for tyrosine kinase inhibitors (TKIs) targeting VEGF and BRAF in thyroid cancer (24:20)
- Safety and tolerability of sorafenib and lenvatinib; management of BRAF-mutated disease (34:49)
- Management of tumors in patients with RET alterations or NTRK fusions; therapies for medullary tumors (39:28)
- Case: A woman in her early 60s with metastatic papillary thyroid cancer; ongoing research combining TKIs and immunotherapy for anaplastic thyroid cancer (50:35)
- Case: A man in his early 40s presenting with severe diarrhea and metastatic medullary thyroid cancer (1:00:54)
CME information and select publications
